文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

2019-20 季节性流感疫苗效果中期估计——美国,2020 年 2 月

Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2020-02-21

2019-20 流感季流感样疾病活动自 2019 年 11 月 9 日当周起超过全国基线,为 2009 年甲型 H1N1 大流行以来最早开始。美国流感疫苗效果网络 2019 年 10 月 23 日至 2020 年 1 月 25 日纳入 4,112 名儿童和成人,估算疫苗对任何流感病毒相关就诊急性呼吸道疾病的总体效果为 45%(95%CI=36%-53%)。

要点

  • 疫苗对任何流感病毒相关就医 ARI 的总体效果为 45%(95%CI=36%-53%)。
  • 对 B/Victoria 型流感效果为 50%(95%CI=39%-59%),对甲型 H1N1pdm09 为 37%(95%CI=19%-52%)。
  • 6 月龄至 17 岁儿童和青少年中疫苗保护效果为 55%(95%CI=42%-65%)。

核心结论

  • 2019-20 流感季中期疫苗效果估计与既往流感季疫苗抗原匹配时的 40%-60% 范围一致,疫苗已显著减少本季迄今与流感相关的就医。

研究设计与样本

  • 使用美国流感疫苗效果网络 2019 年 10 月 23 日至 2020 年 1 月 25 日纳入的 4,112 名儿童和成人数据的中期报告。

主要发现

  • 疫苗对任何流感病毒相关就医急性呼吸道疾病的总体效果为 45%(95%CI=36%-53%)。
  • 对 B/Victoria 型流感病毒的效果为 50%(95%CI=39%-59%)。
  • 对甲型 H1N1pdm09 流感病毒的效果为 37%(95%CI=19%-52%)。
  • 6 月龄至 17 岁儿童和青少年中疫苗效果为 55%(95%CI=42%-65%)。

关键数值与推荐

  • 美国推荐所有 ≥6 月龄者每年接种季节性流感疫苗。
  • 美国 CDC 建议医疗服务提供者继续为 ≥6 月龄者接种流感疫苗,因流感活动持续且疫苗仍可预防当前流行及本季后期可能出现的其他流感病毒相关疾病、住院和死亡。

临床怎么用

  • 美国 CDC 建议医疗服务提供者继续为 ≥6 月龄者接种流感疫苗,因流感活动持续且疫苗仍可预防当前流行及本季后期可能出现的其他流感病毒相关疾病、住院和死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

During the 2019-20 influenza season, influenza-like illness (ILI)* activity first exceeded the national baseline during the week ending November 9, 2019, signaling the earliest start to the influenza season since the 2009 influenza A(H1N1) pandemic. Activity remains elevated as of mid-February 2020. In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months (1). During each influenza season, CDC estimates seasonal influenza vaccine effectiveness in preventing laboratory-confirmed influenza associated with medically attended acute respiratory illness (ARI). This interim report used data from 4,112 children and adults enrolled in the U.S. Influenza Vaccine Effectiveness Network (U.S. Flu VE Network) during October 23, 2019-January 25, 2020. Overall, vaccine effectiveness (VE) against any influenza virus associated with medically attended ARI was 45% (95% confidence interval [CI] = 36%-53%). VE was estimated to be 50% (95% CI = 39%-59%) against influenza B/Victoria viruses and 37% (95% CI = 19%-52%) against influenza A(H1N1)pdm09, indicating that vaccine has significantly reduced medical visits associated with influenza so far this season. Notably, vaccination provided substantial protection (VE = 55%; 95% CI = 42%-65%) among children and adolescents aged 6 months-17 years. Interim VE estimates are consistent with those from previous seasons, ranging from 40%-60% when influenza vaccines were antigenically matched to circulating viruses. CDC recommends that health care providers continue to administer influenza vaccine to persons aged ≥6 months because influenza activity is ongoing, and the vaccine can still prevent illness, hospitalization, and death associated with currently circulating influenza viruses as well as other influenza viruses that might circulate later in the season.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Dawood FS, Chung JR, Kim SS, et al. Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020. MMWR Morb Mortal Wkly Rep. 2020. PMID: 32078591. doi:10.15585/mmwr.mm6907a1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。